BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 21994416)

  • 1. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
    Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
    Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).
    Sha D; Lee AM; Shi Q; Alberts SR; Sargent DJ; Sinicrope FA; Diasio RB
    Clin Cancer Res; 2014 Jun; 20(12):3319-27. PubMed ID: 24727325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
    Kjersem JB; Ikdahl T; Guren T; Skovlund E; Sorbye H; Hamfjord J; Pfeiffer P; Glimelius B; Kersten C; Solvang H; Tveit KM; Kure EH
    BMC Cancer; 2012 Nov; 12():534. PubMed ID: 23167843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.
    Saridaki Z; Weidhaas JB; Lenz HJ; Laurent-Puig P; Jacobs B; De Schutter J; De Roock W; Salzman DW; Zhang W; Yang D; Pilati C; Bouché O; Piessevaux H; Tejpar S
    Clin Cancer Res; 2014 Sep; 20(17):4499-4510. PubMed ID: 25183481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis.
    Langevin SM; Christensen BC
    Cancer Med; 2014 Oct; 3(5):1385-95. PubMed ID: 24890702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer.
    De Ruyck K; Duprez F; Ferdinande L; Mbah C; Rios-Velazquez E; Hoebers F; Praet M; Deron P; Bonte K; Speel EJ; Libbrecht L; De Neve W; Lambin P; Thierens H
    Cancer Epidemiol; 2014 Oct; 38(5):591-8. PubMed ID: 25127693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
    Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
    Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.
    Uvirova M; Simova J; Kubova B; Dvorackova N; Tomaskova H; Sedivcova M; Dite P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):466-71. PubMed ID: 26077004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS-LCS6 genotype as a prognostic marker in early-stage CRC--letter.
    Ryan BM; Robles AI; Harris CC
    Clin Cancer Res; 2012 Jun; 18(12):3487-8; author reply 3489. PubMed ID: 22669132
    [No Abstract]   [Full Text] [Related]  

  • 10. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.
    Christensen BC; Moyer BJ; Avissar M; Ouellet LG; Plaza SL; McClean MD; Marsit CJ; Kelsey KT
    Carcinogenesis; 2009 Jun; 30(6):1003-7. PubMed ID: 19380522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
    Ratner ES; Keane FK; Lindner R; Tassi RA; Paranjape T; Glasgow M; Nallur S; Deng Y; Lu L; Steele L; Sand S; Muller RU; Bignotti E; Bellone S; Boeke M; Yao X; Pecorelli S; Ravaggi A; Katsaros D; Zelterman D; Cristea MC; Yu H; Rutherford TJ; Weitzel JN; Neuhausen SL; Schwartz PE; Slack FJ; Santin AD; Weidhaas JB
    Oncogene; 2012 Oct; 31(42):4559-66. PubMed ID: 22139083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease.
    Ruzzo A; Graziano F; Vincenzi B; Canestrari E; Perrone G; Galluccio N; Catalano V; Loupakis F; Rabitti C; Santini D; Tonini G; Fiorentini G; Rossi D; Falcone A; Magnani M
    Oncologist; 2012; 17(6):823-9. PubMed ID: 22584434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
    Sclafani F; Chau I; Cunningham D; Peckitt C; Lampis A; Hahne JC; Braconi C; Tabernero J; Glimelius B; Cervantes A; Begum R; Gonzalez De Castro D; Hulkki Wilson S; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Valeri N
    Ann Oncol; 2015 Sep; 26(9):1936-1941. PubMed ID: 26162609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A let-7 KRAS rs712 polymorphism increases colorectal cancer risk.
    Pan XM; Sun RF; Li ZH; Guo XM; Zhang Z; Qin HJ; Xu GH; Gao LB
    Tumour Biol; 2014 Jan; 35(1):831-5. PubMed ID: 23975373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis.
    Ulusan M; Sen S; Yilmazer R; Dalay N; Demokan S
    Pathol Res Pract; 2022 Nov; 239():154147. PubMed ID: 36228348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer.
    Huang CJ; Teng HW; Chien CC; Lin JK; Yang SH
    PLoS One; 2014; 8(6):e65117. PubMed ID: 23755178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association analysis of miRNA-related genetic polymorphisms in miR-143/145 and KRAS with colorectal cancer susceptibility and survival.
    Wang D; Liu Q; Ren Y; Zhang Y; Wang X; Liu B
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33825830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.
    Sebio A; Paré L; Páez D; Salazar J; González A; Sala N; del Río E; Martín-Richard M; Tobeña M; Barnadas A; Baiget M
    Pharmacogenet Genomics; 2013 Mar; 23(3):142-7. PubMed ID: 23324806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer.
    Kang M; Shen XJ; Kim S; Araujo-Perez F; Galanko JA; Martin CF; Sandler RS; Keku TO
    Cancer Biomark; 2013; 13(5):359-66. PubMed ID: 24440976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.
    Kundu ST; Nallur S; Paranjape T; Boeke M; Weidhaas JB; Slack FJ
    Cell Cycle; 2012 Jan; 11(2):361-6. PubMed ID: 22189714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.